Literature DB >> 19231294

Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Mei-Chuan Ko1, Norah N Naughton.   

Abstract

UNLABELLED: Nociceptin/orphanin FQ (N/OFQ) is the endogenous peptide for the NOP receptors. Depending on the doses, intrathecal administration of N/OFQ has dual actions (ie, hyperalgesia and antinociception) in rodents. However, the pharmacological profile of intrathecal N/OFQ is not fully known in primates. The aim of this study was to investigate behavioral effects of intrathecal N/OFQ over a wide dose range and to compare its effects with ligands known to produce hyperalgesia or antinociception in monkeys. Intrathecal N/OFQ from 1 fmol to 1 nmol did not produce any hyperalgesic or scratching responses. In contrast, intrathecal substance P 100 nmol produced hyperalgesia, and intrathecal DAMGO 10 nmol produced antinociception. At the dose range between 10 nmol and 1 micromol, intrathecal N/OFQ dose-dependently produced thermal antinociception against a noxious stimulus in 2 intensities. More importantly, N/OFQ in combined with intrathecal morphine dose-dependently potentiated morphine-induced antinociception without inhibiting morphine-induced itch/scratching. Taken together, this study is the first to provide a unique functional profile of intrathecal N/OFQ over a wide dose range in primates. Intrathecal N/OFQ produces thermal antinociception without anti-morphine actions or scratching responses, indicating that N/OFQ or NOP receptor agonists represent a promising target as spinal analgesics. PERSPECTIVE: Intrathecal administration of N/OFQ only produced thermal antinociception, not hyperalgesia, in monkeys. In addition, intrathecal N/OFQ does not have anti-morphine actions or itch/scratching responses. This study strongly supports the therapeutic potential of N/OFQ or NOP receptor agonists as spinal analgesics for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19231294      PMCID: PMC2797530          DOI: 10.1016/j.jpain.2008.11.006

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  45 in total

1.  An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception.

Authors:  M C Ko; N N Naughton
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

2.  Highly potent nociceptin analog containing the Arg-Lys triple repeat.

Authors:  K Okada; T Sujaku; Y Chuman; R Nakashima; T Nose; T Costa; Y Yamada; M Yokoyama; A Nagahisa; Y Shimohigashi
Journal:  Biochem Biophys Res Commun       Date:  2000-11-19       Impact factor: 3.575

3.  Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain.

Authors:  C R Neal; H Akil; S J Watson
Journal:  J Chem Neuroanat       Date:  2001-11       Impact factor: 3.052

4.  Involvement of tachykinin NK1 receptors in nociceptin-induced hyperalgesia in mice.

Authors:  C Sakurada; S Sakurada; S Katsuyama; J Sasaki; K Tan-No; T Sakurada
Journal:  Brain Res       Date:  1999-09-11       Impact factor: 3.252

5.  Orphanin FQ inhibits capsaicin-induced thermal nociception in monkeys by activation of peripheral ORL1 receptors.

Authors:  M C H Ko; N N Naughton; J R Traynor; M S Song; J H Woods; K C Rice; A T McKnight
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

6.  In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.

Authors:  S Ozaki; H Kawamoto; Y Itoh; M Miyaji; T Azuma; D Ichikawa; H Nambu; T Iguchi; Y Iwasawa; H Ohta
Journal:  Eur J Pharmacol       Date:  2000-08-18       Impact factor: 4.432

7.  Responses of superficial dorsal horn neurons to intradermal serotonin and other irritants: comparison with scratching behavior.

Authors:  Steven L Jinks; E Carstens
Journal:  J Neurophysiol       Date:  2002-03       Impact factor: 2.714

8.  Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.

Authors:  M C Holden Ko; Heeseung Lee; Michael S Song; Katarzyna Sobczyk-Kojiro; Henry I Mosberg; Shiroh Kishioka; James H Woods; Norah N Naughton
Journal:  J Pharmacol Exp Ther       Date:  2003-04       Impact factor: 4.030

9.  The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential.

Authors:  David G Lambert
Journal:  Nat Rev Drug Discov       Date:  2008-08       Impact factor: 84.694

10.  Autoradiographic localization of (125)i[Tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS.

Authors:  K E Bridge; A Wainwright; K Reilly; K R Oliver
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  35 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats.

Authors:  Pin-Yen Su; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2011-03-18       Impact factor: 4.030

3.  Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.

Authors:  Devki D Sukhtankar; Nurulain T Zaveri; Stephen M Husbands; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2013-05-07       Impact factor: 4.030

Review 4.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

5.  Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Authors:  Omar S Mabrouk; Riccardo Viaro; Mattia Volta; Ada Ledonne; Nicola Mercuri; Michele Morari
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

6.  Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.

Authors:  A Rizzi; D D Sukhtankar; H Ding; K Hayashida; C Ruzza; R Guerrini; G Calò; M C Ko
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

7.  Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Authors:  Devki D Sukhtankar; Heeseung Lee; Kenner C Rice; Mei-Chuan Ko
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

Review 8.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

Review 9.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

10.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.